Microba Life Sciences Ltd (MAP) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.184x

Based on the latest financial reports, Microba Life Sciences Ltd (MAP) has a cash flow conversion efficiency ratio of -0.184x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.70 Million ≈ $-4.04 Million USD) by net assets (AU$31.08 Million ≈ $21.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MAP stock market capitalisation for the company's overall valuation and market capitalisation.

Microba Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)

This chart illustrates how Microba Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Microba Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Microba Life Sciences Ltd ranked by their cash flow conversion efficiency. See MAP cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Change Financial Ltd AU:CCA	0.002x
ACE LIBERTY+STONE LS -25 F:8MW	N/A
Race Eco Chain Limited NSE:RACE	0.039x
Performance Shipping Inc NASDAQ:PSHG	0.043x
Master Pack Group Bhd KLSE:7029	0.008x
UTStarcom Holdings Corp NASDAQ:UTSI	-0.080x
Aarvi Encon Limited NSE:AARVI	0.045x
Andalan Perkasa Abadi Tbk PT JK:NASA	0.000x

Annual Cash Flow Conversion Efficiency for Microba Life Sciences Ltd (2018–2024)

The table below shows the annual cash flow conversion efficiency of Microba Life Sciences Ltd from 2018 to 2024. View Microba Life Sciences Ltd stock quote for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$32.49 Million ≈ $22.99 Million	AU$-12.01 Million ≈ $-8.50 Million	-0.370x	+2.12%
2023-12-31	AU$41.22 Million ≈ $29.16 Million	AU$-15.57 Million ≈ $-11.01 Million	-0.378x	-18.01%
2022-12-31	AU$38.72 Million ≈ $27.40 Million	AU$-12.39 Million ≈ $-8.77 Million	-0.320x	-2.72%
2021-12-31	AU$33.54 Million ≈ $23.73 Million	AU$-10.45 Million ≈ $-7.39 Million	-0.312x	+35.20%
2020-12-31	AU$14.94 Million ≈ $10.57 Million	AU$-7.18 Million ≈ $-5.08 Million	-0.481x	+14.32%
2019-12-31	AU$7.70 Million ≈ $5.45 Million	AU$-4.32 Million ≈ $-3.06 Million	-0.561x	-94.62%
2018-12-31	AU$12.56 Million ≈ $8.88 Million	AU$-3.62 Million ≈ $-2.56 Million	-0.288x	--

About Microba Life Sciences Ltd

AU:MAP Australia Diagnostics & Research

Market Cap

$21.97 Million

AU$31.06 Million AUD

Market Cap Rank

#24886 Global

#1031 in Australia

Share Price

AU$0.05

Change (1 day)

+2.00%

52-Week Range

AU$0.04 - AU$0.10

All Time High

AU$0.44